Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease

NCT06392425 | Not Yet Recruiting

• 1 other identifier: caspase 3 and ADAM 17 in CKD
• Study Type: observational
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients
2. 2.Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease
3. 3.Compare serum ADAM 17 and Caspase 3 levels in Diabetic Chronic kidney disease patients and Non Diabetic Chronic kidney disease patients

Conditions

Chronic Kidney Diseases

Outcome Measures

Primary Outcomes (1)

• To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients

  Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease

  baseline

Study Arms (6)

- Group (1): stage(1) CKD patient group

Stage 1 of CKD (eGFR of 90 or greater)

Other: caspase 3 and ADAM 17 biomarkers

-Group (2): stage (2) CKD patient group

Stage 2 of CKD (eGFR between 60 and 89)

Other: caspase 3 and ADAM 17 biomarkers

-Group (3) :stage(3) CKD patient group

Stage 3 of CKD (eGFR between 30 and 59)

Other: caspase 3 and ADAM 17 biomarkers

-Group (4) :stage (4) CKD patient group

Stage 4 of CKD (eGFR between 15 and 29)

Other: caspase 3 and ADAM 17 biomarkers

-Group (5):stage(5) CKD patient group

Stage 5 of CKD (eGFR less than 15)

Other: caspase 3 and ADAM 17 biomarkers

-Group (6) :control Group

apparently healthy individuals with matched age and sex are included in this study as a control group for comparison

Other: caspase 3 and ADAM 17 biomarkers

Interventions

caspase 3 and ADAM 17 biomarkers OTHER

Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

- Group (1): stage(1) CKD patient group; -Group (2): stage (2) CKD patient group; -Group (3) :stage(3) CKD patient group; -Group (4) :stage (4) CKD patient group; -Group (5):stage(5) CKD patient group; -Group (6) :control Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with chronic kidney disease with different contributing factors e.g Diabetis mellitus , Hypertension,autoimmune diseases.

You may qualify if:

• Patients with chronic kidney disease
• Patients with different contributing factors e.g Diabetis mellitus, Hypertension ,autoimmune diseases.

You may not qualify if:

• Patients with pulmonary oedema or hepatic disease .
• Patients with known any organ malignancy.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (6)

• Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M, Kasiske B, Kottgen A, Kretzler M, Levey AS, Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N, Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle KR, Wheeler DC, Eckardt KU; ISN Global Kidney Health Summit participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20.

  PMID: 28434650 BACKGROUND

• Iino Y. [Definition of CKD and classification of CKD stage]. Nihon Rinsho. 2008 Sep;66(9):1645-9. Japanese.

  PMID: 18788389 BACKGROUND

• Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016 Feb;12(2):73-81. doi: 10.1038/nrneph.2015.173. Epub 2015 Nov 10.

  PMID: 26553517 BACKGROUND

• Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010 Apr;45(2):146-69. doi: 10.3109/10409231003628015.

  PMID: 20184396 BACKGROUND

• Palau V, Riera M, Duran X, Valdivielso JM, Betriu A, Fernandez E, Pascual J, Soler MJ. Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2020 Jan 1;35(1):130-138. doi: 10.1093/ndt/gfy240.

  PMID: 30102333 BACKGROUND

• Clementi A, Virzi GM, Manani SM, de Cal M, Battaglia GG, Ronco C, Zanella M. Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease. J Clin Med. 2023 Aug 28;12(17):5616. doi: 10.3390/jcm12175616.

  PMID: 37685683 BACKGROUND

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Caspase 3

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Caspases, Effector; Caspases; Cysteine Endopeptidases; Cysteine Proteases; Peptide Hydrolases; Hydrolases; Enzymes; Enzymes and Coenzymes; Endopeptidases; Apoptosis Regulatory Proteins; Intracellular Signaling Peptides and Proteins; Proteins; Amino Acids, Peptides, and Proteins

Study Officials

• samar salah

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

samar salah

CONTACT

01002753465; samarsalah24194@gmail.com

Eman Mohammed

CONTACT

01003030752; Dr.emanmohammed@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant lecturer

Study Record Dates

• First Submitted: April 26, 2024
• First Posted: April 30, 2024
• Study Start: April 26, 2024
• Primary Completion (Estimated): March 31, 2027
• Study Completion (Estimated): October 31, 2027
• Last Updated: May 1, 2024

Record last verified: 2024-04